A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)

N/ACompletedNCT01535118

ALK-Abelló A/S2,765 enrolled

Overview

This study will gather information on allergic rhinoconjunctivitis from surveys completed by adults and children.

Study Type

OBSERVATIONAL

Enrollment

2,765

Conditions

Allergic Rhinoconjunctivitis

Eligibility

Sex: ALLMin age: 5 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with hay fever, rhinitis or nasal and/or eye allergies and display symptoms of sneezing, itching, watery eyes, nasal congestion, or other nasal or eye allergy symptoms over the past 12 months OR take any medication for their hay fever, rhinitis, nasal or eye allergies * 5 years of age or older * Have a telephone Exclusion Criteria: * If less than 18 years old and there is no adult available that is knowledgeable about the participant's health

Outcomes

Primary Outcomes

Percentage of Participants Who Experienced Daily Symptoms Due to Allergic Rhinoconjunctivitis (ARC)

Participants were asked about the frequency and severity of ARC symptoms when allergies were at their worst. The percentages of participants who experienced different symptoms of ARC on a daily basis when allergies were at their worst were calculated.

Time frame: Within 12 months prior to survey

Percentage of Participants Who Experienced Work or School Absence Due to ARC in the Past 12 Months

Participants were asked about the impact of ARC on loss of work and school time. The percentage of participants who experienced work or school absence due to ARC in the prior 12 months was calculated.

Time frame: Within 12 months prior to survey

Percentage of Participants Who Used Medication to Treat ARC in the Past 12 Months

Participants were asked about prescription and over-the-counter medication use for ARC. The percentages of participants who used prescription and/or over-the-counter medication to treat ARC in the past 12 months were calculated.

Time frame: Within 12 months prior to survey

Percentage of Participants Who Received Immunotherapy to Treat ARC

Participants who had ever received immunotherapy for ARC were asked about the type of immunotherapy - subcutaneous or sublingual - received. The percentage of participants who received immunotherapy to treat ARC was calculated.

Time frame: Within 12 months prior to survey

Percentage of Participants Who Received Allergy Shots and Required Supplemental Prescription Allergy Medication

Participants who received subcutaneous immunotherapy (allergy shots) were asked about prescription and over-the-counter medication use. The percentage of participants who received allergy shots to treat ARC, had not taken over-the-counter allergy medication and required supplemental prescription allergy medication for ARC was calculated.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)

Overview

Conditions

Eligibility

Outcomes

Primary Outcomes

Secondary Outcomes